Welcome to our dedicated page for Regenerx Biopharmaceuticals news (Ticker: RGRX), a resource for investors and traders seeking the latest updates and insights on Regenerx Biopharmaceuticals stock.
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) is a clinical-stage biopharma leader developing tissue repair therapies through its patented thymosin beta 4 platform. This page serves as the definitive source for verified updates on the company's three flagship drug candidates: RGN-137 (dermal wounds), RGN-259 (ocular disorders), and RGN-352 (systemic applications).
Investors and industry observers will find timely updates on clinical trial progress, strategic partnerships in key global markets, and regulatory developments. The resource consolidates essential information including intellectual property milestones, financial restructuring efforts, and partner-funded research initiatives.
Key content categories include clinical trial phase updates, partnership announcements with U.S./Asian collaborators, SEC filing disclosures, and progress reports on the company's 75+ patent portfolio. All information is sourced directly from company communications to ensure compliance and accuracy.
Bookmark this page for streamlined access to RegeneRx's latest developments in tissue regeneration science and corporate strategy. For direct inquiries, reference the official company website and investor relations contacts provided in all filings.
On Sept. 8, 2020, RegeneRx Biopharmaceuticals (OTCQB: RGRX) announced that a research paper highlights the potential of Thymosin beta 4 (Tβ4) in treating COVID-19. The study indicates Tβ4 may induce fibrinolysis, reducing blood clots in patients. Researchers noted that men suffering from COVID-19 are significantly more at risk compared to women, possibly due to genetic factors linked to Tβ4. The findings suggest Tβ4 could mitigate serious symptoms of COVID-19, especially in vulnerable populations. RegeneRx continues to develop Tβ4-based therapies, including a candidate for COVID-19 treatment.
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) announced that its joint venture partner, GtreeBNT, is accelerating the ARISE-3 phase 3 clinical trial for dry eye syndrome. The trial, which experienced delays due to COVID-19, now includes 19 clinical sites and is set to enroll 700 patients by November 2020. RGN-259 eye drops have shown promising efficacy in previous trials and are now classified as biologics, offering 12 years of market exclusivity upon FDA approval. The joint venture also plans a Phase 3 study for neurotrophic keratopathy.
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) announced an update on its Phase 3 dry eye clinical trial (ARISE-3) enrollment status. The company is developing Tβ4 therapeutic peptides for tissue protection and regeneration. Currently, RegeneRx has three drug candidates under clinical development for various medical indications, including ophthalmic and cardiac uses. The ophthalmic product RGN-259 is particularly noted for its Phase 3 trials aimed at treating dry eye syndrome and neurotrophic keratitis in the U.S.
FAQ
What is the current stock price of Regenerx Biopharmaceuticals (RGRX)?
What is the market cap of Regenerx Biopharmaceuticals (RGRX)?
